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ABSTRACT The X-linked form of Opitz syndrome (OS) is caused by loss of function of the
microtubule-associated MID1 protein. The phenotype of OS includes defects along the central body
axis, namely hypertelorism, cleft lip and palate, hypospadias and cardiac structural anomalies. Here
we describe the isolation and characterisation of full-length cDNA clones representing the chick Mid1
gene and the detailed profile of its expression in stage 7 to 28 chick embryos. Consistent with the
remarkable sequence conservation of MID1 between human and chick was the good correlation of the
pattern of cMid1 expression with the tissues affected in OS. In stage 10 embryos, transcripts were
concentrated in the head mesenchyme which includes migratory neural crest cells. However, the
incomplete overlap with a neural crest marker, Sox10, suggests that Mid1 is a marker for somitomeric
mesoderm and potentially for a subset of neural crest cells. Consistent with this, cMid1 expression was
also detected at later stages in neural crest-derived facial mesenchyme, in the myotome and in the
condensing muscle blocks of the limb. Expression of cMid1 was observed in the neural epithelium of
the forebrain beginning at stage 7 with increased signal in presumptive rhombomeres 2/3. By stage
15, expression is highest in the diencephalon. Other areas with high expression are certain facial
epithelia and the midgut that will give rise to the oesophagus and trachea. These data indicate that
Mid1 plays an evolutionarily conserved developmental function in vertebrates that may involve effects
on cellular proliferation, tissue interactions and morphogenesis.
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Introduction
Opitz GBBB syndrome (OS; Opitz syndrome) is a classic
example of a defect of the primary midline developmental field.
Despite marked interindividual variability in clinical presentation,
the disorder can be recognised by characteristic facies (ocular
hypertelorism and variably cleft lip with or without cleft palate [CL/
P] and laryngotracheo-oesophageal [LTE] clefting) in combination
with difficulty in swallowing (dysphagia), structural heart defects as
well as anal and genital anomalies (Opitz, 1987; Robin et al., 1996).
Part of this complexity may be explained by the possible interaction
between the multiple genetic loci independently implicated in
causation of OS: an X-linked form caused by mutations in the MID1
gene at Xp22.3 (Quaderi et al., 1997; Gaudenz et al., 1998;
Schweiger et al., 1999; Cox et al., 2000) which comprises at least
50% of all OS cases (Cox et al., 2000), and at least one autosomal
form at chromosome 22q11.2 for which the gene has not been
identified (McDonald-McGinn et al., 1995; Robin et al., 1995;
Fryburg et al., 1996). Significantly, this 22q11 interval is also
implicated in a group of disorders collectively known as the 22q11
deletion syndrome (which encompasses DiGeorge and
Velocardiofacial syndromes) that shows some phenotypic overlap
with OS (McDonald-McGinn et al., 1995; Robin et al., 1995). The
22q11 deletion syndrome (also known as CATCH22) represents
one of the most common genetic causes of malformations (Glover,
1995).
The X-linked MID1 gene encodes a protein of 667 amino acids
that is the defining member of a new subclass of the RBCC (RING,
B-box, Coiled-Coil) family of proteins. This subclass is characterised
by the combination of both a fibronectin type III motif and a recently
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Fig. 1. Amino acid alignment of chick Mid1 with human, rat and mouse MID1. (1) Human MID1 - Genbank
accession #AF269101; (2) Rat (R. norvegicus) MID1 - Genbank accession #AF186461; (3) Mouse (M. musculus)
Mid1 (Genbank accession #AF026565); (4) Chick (G. gallus) Mid1 - Genbank accession #AF269102. Black boxes
indicate identical amino acid residues. Human versus rat, 99.1% identity; human versus mouse, 94.9% identity;
human versus chick, 95.4% identity. The RING, B-boxes, coiled-coil, FNIII and C-terminal domains are highlighted.
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defined C-terminal (B30.2-like or SPRY) domain (Short et al., in
preparation). Despite the fact that many RBCC proteins function
within the nucleus (for example, the products of the proto-oncogenes,
PML and RFP, and those with developmental roles, such as
Pleurodeles waltls, PwA33, and Xenopus laevis, XNF7), recent
studies have shown that MID1 associates with cytoplasmic micro-
tubules throughout the cell cycle (Cainarca et al., 1999; Schweiger
et al., 1999).
The majority of mutations in MID1 that cause OS are truncating
mutations with many, but not all, directly affecting the C-terminal
half of the protein (Cox et al., 2000). Significantly, all examined
MID1 mutations disrupt the normal microtubule-associated distri-
bution although not all in the same manner or to the same degree
(Cainarca et al., 1999; Schweiger et al., 1999; Cox et al., 2000),
leading to the belief that the X-linked form of OS is caused by loss
of function of MID1 (Cox et al., 2000).
Although the actual function of MID1 is not known, cell fraction-
ation experiments have demonstrated that MID1 is found as part of
large multiprotein complexes on microtubules (Cainarca et al.,
1999). The recent identification of the Alpha 4 protein, which has
a well-characterised role in regulating PP2-type phosphatases
(Schmelzle and Hall 2000), as a strong interacting partner of
microtubule-bound MID1 may help elucidate the function of MID1
(Liu et al., 2001; Short et al., 2002). The signalling pathway in which
Alpha 4 functions appears to be conserved from yeast through to
mammals and affects a number of aspects of cell-cycle progres-
sion, including the regulation of microtubule structure and function
as well as protein biosynthesis (Goldberg, 1999). It is believed that
the disruption of this Alpha 4-regulated protein phosphatase action
from microtubules may, at least in part, underlie the complex and
variable clinical phenotype of OS.
Studies are currently underway to address the role of the Mid1
gene in mammalian development through the use of cell culture
and gene targeting experiments in mice. The latter is based on
preliminary analysis of the expression of the murine Mid1 gene
over a limited developmental time period, which indicated that its
pattern of expression was largely consistent with the tissues
affected in patients with Opitz syndrome (Dal Zotto et al., 1998).
However, the chick has long been the model system of choice for
studies of neural crest, craniofacial and muscle development due
to the accessibility and manipulability of the embryos. In fact, the
resurgence in interest in the chick as a system in which to
undertake molecular studies has come with the advent of anti-
sense technology, the use of growth factor-soaked beads, and in
vivo electroporation. In order to determine whether the chick could
be utilised as a complementary system in which to investigate the
role of MID1 in craniofacial development, we sought to isolate the
MID1 orthologue from chick and characterise in detail its pattern of
expression throughout the relevant stages of development.
Results
Cloning of Chicken Mid1
Of nearly 50 positively hybridising plaques, eight (clones 5B1,
7B1, 7B2, 8B1, 9B1, 12B1, 16B1 and 16B2) were initially chosen
and successfully purified through additional dilution and plating
series. Insert sizes of the isolated phage ranged from 1.0 kb (7B1)
to 2.0 kb (8B1 and 9B1). Assembly of the sequences revealed an
open reading frame encoding a protein of 667 amino acids.
Comparison of this chick sequence with that of human, rat and
mouse MID1 revealed a striking level of conservation: for example,
the comparison with human MID1 showed 84.4% and 95.4%
identity at the nucleotide (over the complete open reading frame)
and amino acid levels, respectively (see Fig. 1). Even the 88 bp of
5’ untranslated region obtained from these chick cDNAs showed
>80% identity with the human sequence (data not shown). Analysis
of the predicted amino acid sequence using the program Pfam
demonstrated, as expected, that the RBCC, FNIII and C-terminal
domains were each present in the chick protein (Fig. 1). This level
of conservation indicated that this chick sequence was likely to
represent the orthologue of human MID1.
Expression of cMid1 at Embryonic Stages 7 through 28
Preliminary whole mount in situ hybridisation carried out on
stage 19 - 21 embryos showed strong expression in the craniofa-
cial region (Fig. 2 A,C). At stage 19, expression in the frontonasal
mass was strong although this decreased slightly by stage 21,
whereas expression remained strong in the maxillary and man-
dibular processes and the second branchial arch at both stages
(Fig. 2C). Weaker expression was also evident in the caudal
Fig. 2. Whole mount in situ hybridisation using
cMid1 on stage 21 chick embryos. Whole mount in
situ hybridisation using an antisense (A) or sense (B)
cMid1 probe. Using the antisense probe, a high level
of cMid1 expression was detected in the craniofacial
region (arrowheads) and both the forelimb and
hindlimb buds. Weaker expression can also be seen
in the urogenital tract, somites and the gut. (C) In the
craniofacial region, expression was highest in the
maxillary and mandibular prominences as well as
branchial arch 2. Branchial arches 3 and 4, in addition
to the branchial clefts, also express cMid1 but in
these tissues expression was considerably lower
and appeared to be restricted to the caudal half of
each arch. No expression was seen when using the
cMid1 sense probe (B). Abbreviations: BA2-4, bran-
chial arches 2-4; G, gut; H, heart; MX, maxillary
prominence; MN, mandibular prominence; S,
somites; UT, urogenital tract.
A B
C
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Fig. 4. Expression of cMid1 in the dien-
cephalon, myotome, facial prominences and
midgut. (A-C) Frontal sections; (D-G) sagittal
sections. (A-F) are hybridised to and (G) is
immunocytochemistry to the MF-20 antibody.
(A,D) Expression of Mid1 in the ventral and
dorsal diencephalon and base of the allantois.
(B,C) Expression in frontonasal mass mesen-
chyme under brain (arrows) and in maxillary
prominences. There is also strong expression
in the epithelium (arrowheads) and signal in the
midline of the mandible (mandible not in sec-
tion in (C)). (E) Section of body with head
removed. Expression in the midgut (arrow) and
heart. (F,G) near-adjacent sections through the
body with head removed showing strong ex-
pression of Mid1 in the muscle of the limb bud
(arrow in (F)). (G) The trunk myotome expresses
MF-20 and the condensing muscle in the
hindlimb. Scale bar, 500 µm for (A-D); 1 mm for
(E-G). Abbreviations: a, allantois stalk; d, dien-
cephalon; e, eye; fnm, frontonasal mass; h,
heart; hl, hindlimb; m, mesencephalon; md,
mandibular prominence; mx, maxillary promi-
nence; nt, neural tube; r, rhombencephalon; s,
stomach; mt, myotome.
Fig. 3. Expression of cMid1 in the mesoderm, hindbrain and head mesenchyme of stage 10 embryos. (A-C) Coronal sections through hindbrain. (D-
I) Frontal sections stained with toluidine blue adjacent to those used for in situ hybridisation. (B,E,H) Sections to which cMid1 cRNA was hybridised and (C,F,I)
are sections to which cSox10 cRNA, a marker for neural crest cells, was hybridised. Signal is seen as white silver grains on a black background. (B,C) Note
expression of cMid1 in the head mesenchyme compared to the more dorsally expressed Sox10 (arrow in (C)). (E,F) Expression of cMid1 in the head
mesenchyme (arrow in (E)) does not overlap regions expressing Sox10 (arrow in (F)). (H,I) Expression of cMid1 in the head mesenchyme partly overlaps Sox10
expression (arrow in (I)). The section in (I) is more dorsal than the one in (H). There is also expression of cMid1 in the r2/r3 region (arrow in (H)) and in the
neural epithelium at lower levels. Scale bar, 250 µm. Abbreviations: f, forebrain; h, heart; m, mesencephalon; pm, presomitic mesoderm; r1, rhombomere 1.
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portion of branchial arches 3 and 4 (Fig. 2C). Other tissues in which
expression was also detectable included the midgut, urogenital
tract, eyes, heart, the anterior CNS and in a regularly spaced
pattern either side of the neural tube which was likely to be somitic
tissue. Somewhat surprising was the very strong expression in the
developing forelimb and hindlimb buds (Fig. 2A).
Using in situ hybridisation on serial sections of stage 7-10 chick
embryos, we observed expression of cMid in the mesenchyme
adjacent to the mesencephalon and hindbrain (Fig. 3 E,H) how-
ever, in stage 10 embryos, this did not completely overlap with
expression of cSox10, a marker for neural crest cells (Fig. 3 F,I;
Cheng et al., 2000). In coronal sections it was obvious that cSox10
is located at a more dorsal position than the cMid1 expressing
regions (Fig. 3 B,C). In order to see whether these regions of
expression remained separate at older stages, we compared
expression of the two genes in stage 28 embryos. In these sections
it was clear that cSox10 labelled neural crest derived glial cells
(data not shown) and that the early differences in expression of
cMid1 and cSox10 were maintained. In other sections of stage 7-
10 embryos (Fig. 3H), strong cMid1 expression was also seen in
the presomitic mesoderm. Therefore mesodermal expression was
present outside the cranial region of the embryo. There were also
transcripts in neuroepithelium of the forebrain and presumptive
rhombomeres at stage 7. By stage 10 the expression in the
hindbrain was largely restricted to the r2/r3 region.
We observed expression of cMid1 throughout the anterior
neuroepithelium but with higher levels of expression particularly
apparent in the diencephalon at stage 15 (Fig. 4 A,D). At stage 20,
all the facial prominences have formed and there was increased
expression of cMid1 in the central frontonasal mass mesenchyme
and underlying the ventral surface of the brain (Fig. 4B). There was
also expression throughout the maxillary mesenchyme. Epithelial
expression was present in the caudal edge of the frontonasal mass
and medial maxillary prominence. Similar patterns of expression
were maintained at stage 24 (Fig. 4C) and at stage 28 (Fig. 5B).
However at stage 28 there was increased expression at the lateral
corners of the frontonasal mass where fusion with the maxillary
prominences will take place (Will and Meller, 1981; Sun et al.,
2000).
The expression in early mesoderm suggested that later in
development cMid1 might be expressed in mesodermal deriva-
tives such as muscle. Beginning at stage 24 and continuing at
stage 28 we observed strong cMid1 expression in the limb bud
(Figs. 4E, 5F). In order to determine whether the expression was
within muscle, we stained adjacent sections with MF-20, an anti-
body that recognises myosin heavy chain (Bader et al., 1982). We
found that MF-20 staining overlapped regions of cMid1expression
in the limbs and also in the myotome (Fig. 5 C,D,G,H). The dorsal
myotome expresses higher levels of cMid1 than do other regions
of the myotome (compare Fig. 5 C,D). In addition to skeletal
muscle, Mid1 was expressed in cardiac muscle (Fig. 5 I,J). cMid1
was also expressed in the dermis covering the brain, in mesen-
chyme ventral to the brain and within the facial prominences. Thus
cMid1 was clearly expressed in other mesenchymal cell types that
were not of the muscle lineage.
Some of the most consistent features of OS are the abnormali-
ties of the larynx, trachea and oesophagus. We were therefore not
surprised to see that cMid1 was expressed in the midgut, which
gives rise to the tracheal region (Fig. 4E) and later, at stage 28, in
the mesenchyme surrounding the trachea and oesophagus (Fig.
Fig. 5. Expression of MF-20 and cMid1 in the stage 28 embryo. (A,B)
Frontal sections through the facial region showing little MF-20 staining but
localised expression of cMid1 in the mesenchyme (arrows) and in the
frontonasal mass and maxillary epithelium (arrowheads). (C,D) Sections
through the neck showing expression of MF-20 in the myotome and
overlap of cMid1 transcripts in the dorsal myotome (arrow in (D)). (E,F)
Sagittal sections through the hindlimb showing that MF-20 labels condens-
ing muscle blocks and this overlaps the areas expressing cMid1. (G,H)
Sagittal sections through the trunk illustrating MF-20 expression in the
myotome overlapping expresion of cMid1. (I,J) Sagittal sections through
the mid-trunk and heart showing strong MF-20 staining in the heart. The
trachea, oesophagus and heart express cMid1. Blood in the heart shows
dense silvergrains. Scale bar, 500 µm for all panels. Abbreviations: a,
atrium; c, cartilage elements; e, oesophagus; fnm, frontonasal mass; lnp,
lateral nasal prominence; m, muscle blocks; mt, myotome; mx, maxillary
prominence; nc, notochord; t, trachea; v, ventricle.
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5J). Anomalies of the umbilicus, although less frequent, have also
been reported in OS. Consistent with this, we also saw strong
expression in the allantoic bud, a region analogous to the umbilical
cord in mammals (Fig. 4D).
Discussion
Mid1 from Chicks and Humans exhibits a High Level of
Sequence Conservation
The classic presentation of Opitz syndrome includes as its
diagnostic features: a characteristic facial appearance (most nota-
bly ocular hypertelorism), dysphagia (difficulty in swallowing), and
genital anomalies such as hypospadias in males. However, there
are frequently other associated malformations, such as cardiac
septation defects, labiopalatine and laryngo-tracheo-oesophageal
anomalies, and an imperforate or anteriorly displaced anus. This
array of features indicates that the disorder likely arises as a result
of a disturbance to the midline developmental field, whereby the
proper formation of structures along the midline body axis is
compromised (Opitz, 1987; Robin et al., 1996). In addition to the
phenotypic variability in Opitz syndrome, there is genetic heteroge-
neity with an indistinguishable clinical presentation resulting from
abnormalities of either the X-linked gene, MID1 (Quaderi et al.,
1997; Gaudenz et al., 1998; Schweiger et al., 1999; Cox et al.,
2000), or an as yet unidentified autosomal gene residing at
22q11.2 (Robin et al., 1995). Studies are ongoing in a number of
laboratories including our own using the mouse as a model system.
However, the chicken system represents a more accessible and
widely used system to address mechanisms of craniofacial devel-
opment. Therefore, in order to investigate whether the chick
system would be suitable for, and amenable to, investigations of
MID1 function during development, we undertook to identify the
chick Mid1 gene and compared its profile of expression during
development to that of murine Mid1 and its human counterpart by
inference from the clinical features of the disease.
Numerous cDNA clones were isolated that covered a full open
reading frame of 2001 bp. The protein encoded by this open
reading frame is 667 amino acids in length and shows over 95%
identity (99.3% similarity) with human MID1, indicating that these
clones likely represent the orthologous chick Mid1 sequence.
Using in situ hybridisation initially on whole mount chick embryos
and then on serial sections of embryos from stage 7 through 28, we
have performed a detailed analysis of cMid1 expression. We have
shown that the pattern of cMid1 gene expression is largely consis-
tent with the clinical features seen in Opitz syndrome although a
few differences between the chick and the previously reported
mouse Mid1 expression patterns were observed (see below).
cMid1 Expression correlates well with the Tissues Affected in
Opitz Syndrome
The combination of features in Opitz syndrome such as the
characteristic facial abnormalities and cardiac septation defects
shows some overlap with the other disorders (for example, DiGeorge
and Velocardiofacial syndromes) collectively referred to as the
22q11.2 deletion syndrome. These latter disorders have long been
considered to arise as a result of defects in neural crest cell
contribution to various regions of the body (Scambler, 2000). It is,
therefore, conceivable that the Opitz syndrome phenotype could
also result from a defect in contribution from the neural crest.
Indeed, we observed expression of cMid1 in neuroepithelium but
found there was only partial overlap in expression with a neural
crest-specific marker, cSox10, suggesting that cMid1 is not ex-
pressed in the majority of migrating and proliferating neural crest
cell populations. However, these observations do not exclude the
possibility that a disruption to microtubule-linked functions, as a
result of MID1 mutation, could delay or perturb neural crest cell
release from the dorsal neural tube. In this regard, one intriguing
possibility is that mutation (ie. loss of function) of MID1 perturbs the
epithelial-mesenchyme transition (EMT) that occurs concomitant
with release of neural crest cells from the neural folds. A similar
effect on EMT processes could also be envisaged during fusion of
the paired craniofacial primordia, lateral and medial nasal pro-
cesses and frontonasal mass. This process of fusion is critical for
the formation of the lip and palate (Sun et al., 2000), and when
perturbed could be expected to result in cleft lip with or without cleft
palate that is seen in many cases of Opitz syndrome.
From their preliminary studies in mice, Dal Zotto and colleagues
concluded that the murine Mid1 gene was expressed predomi-
nantly in undifferentiated cell populations and therefore the OS
phenotype was likely due to abnormal cellular proliferation (Dal
Zotto et al., 1998). Consistent with this, we did observe expression
of chick Mid1 at the lateral edges of the frontonasal mass mesen-
chyme and throughout the maxillary mesenchyme, which are both
areas of high cellular proliferation (Peterka and Jelinek, 1983;
McGonnell et al., 1998). Therefore, Mid1 may have some role in
outgrowth of the corners of the frontonasal prominence as they
meet and fuse with the maxillary prominences (Will and Meller,
1981). Moreover, the high expression of cMid1 in the facial epithe-
lia suggests that the gene may be involved in epithelial-mesenchy-
mal interactions, as facial epithelium is required for outgrowth of
underlying mesenchyme (Wedden, 1987; Richman and Tickle,
1989). Whatever the underlying cellular or tissue problem in OS,
Mid1 clearly plays an important role during craniofacial, midgut and
muscle morphogenesis and further studies are needed to clarify
the developmental role(s) of this RBCC protein. In this regard, it will
be of interest to see whether factors such as Sonic hedgehog
(Shh), which controls the width of the frontonasal mass (Hu and
Helms 1999), and has overlapping expression in the frontonasal
mass epithelium (Helms et al., 1997), either affects, or is associ-
ated with, expression of cMid1.
Significantly, the correlation with the array of anomalies in Opitz
syndrome extends also to other embryological tissues in which the
chick Mid1 gene is expressed. For example, we observed strong
cMid1 expression in the allantoic bud, a region analogous to the
umbilical cord in mammals. This allantoic expression would there-
fore correlate with the occasional finding of umbilical hernias in
patients with Opitz syndrome. Notably, however, there are some
apparent differences between the expression pattern we have
observed for chick Mid1 and that reported for the mouse Mid1 by
Quaderi and colleagues (Quaderi et al., 1997; Dal Zotto et al.,
1998). Most striking was that we detected expression of cMid1 in
the myotome as well as very prominent expression in the muscle
blocks of the limbs, whereas neither was mentioned for mMid1.
Although it is not known whether the human MID1 is expressed in
muscle, one classic feature of the OS phenotype (i.e. dysphagia)
could be explained by abnormal muscle morphogenesis or func-
tion. Limb anomalies, however, are uncommon in Opitz syndrome
with upper limb dystonia and limb / digit shortening representing
the few examples (Williams and Frias, 1987; Cox et al., 2000). One
other notable difference between chicks and mice is that we have
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observed expression of cMid1 in the heart, whereas Quaderi and
colleagues highlight that the fetal mouse heart is devoid of mMid1
expression (Quaderi et al., 1997; Dal Zotto et al., 1998). Finally,
one of the characteristic clinical features of male OS patients is the
genital anomaly of hypospadias. We have not been able to report
whether cMid1 is expressed in analogous developing tissue as,
unlike mammals, the chicken embryo does not develop a genital
tubercle until stage 30 and the genital tubercle is rudimentary until
after hatching. For these reasons the chicken is not the best model
system for studying the role of cMid1 in formation of the various
anomalies in the genitourinary system seen in Opitz syndrome.
The array of anomalies seen in patients harbouring loss of
function mutations in MID1 highlights the critical role that this
microtubule-associated protein plays in development of the cran-
iofacial complex and other organ systems. Although we and others
have recently implicated MID1 in the regulation of PP2-type serine/
threonine phosphatase activity (i.e. the modulation of signal trans-
duction events) and hence in the regulation of processes such as
cell cycle progression and protein biosynthesis (Liu et al., 2001;
Short et al., 2002), there are likely numerous other roles for MID1
which may become apparent with the identification of the other
factors present in the MID1 macromolecular complexes. Our
isolation of the highly conserved chick Mid1 gene and demonstra-
tion that its developmental pattern of expression correlates well
with the tissues affected in Opitz syndrome will provide new
opportunities by which to investigate the role of this gene and the
pathophysiological consequences of its mutation.
Materials and Methods
Isolation and Characterisation of Chicken Mid1 Clones
Full-length cDNA clones representing chicken Mid1 were isolated by
screening 106 pfu from an E4.5-5 whole chick embryo cDNA library. As a
probe, a 1.4kb human MID1 cDNA fragment was employed that was
generated by PCR using the full-length human MID1 cDNA as template with
the 5’MID-fusion (5’-GTG AAT TCC TGA AGA TGG AAA CAC TGG AGT
C-3’; position –7 to +17) and MIDdelCTD (5’-CTG CTC GAG CCC GCC TAG
TTG ATG GCC TTS ACC-3’; position +1410 to +1386) primers. These
primers were designed to incorporate either an EcoRI and XhoI restriction
site (indicated in bold type in the relevant primer sequences) to facilitate
cloning of the product. Positively hybridising plaques were purified through
additional dilution and plating series before phage DNA was isolated.
Automated DNA sequencing was performed by cycle sequencing with
Applied Biosystems Dye Terminator chemistry and analysed on an Applied
Biosystems 377 sequencer (Institute for Medical and Veterinary Science
Sequencing Service, Adelaide). The entire sequence of selected positive
clones was determined by a combined end-sequencing and primer walking
strategy and assembled in DNAsis v2.0 (Hitachi). cDNA sequence analysis
and searches were performed either locally using DNAsis v2.0 or via the
internet using BLAST at the NCBI (http://www.ncbi.nlm.nih.gov/). The
predicted amino acid sequence was also analysed using the web-based
program Pfam.
In Situ Hybridisation on Whole Mount and Serially Sectioned Chick
Embryos
For whole mount in situ hybridisation, we generated both digoxygenin-
labelled sense and anti-sense RNA probes by in vitro transcription from
templates derived by either NotI or NsiI linearisation of clone 7B2 in pGEM7
(for the sense and anti-sense probes respectively). Hybridisation, washes
and detection were performed on stage 19 - 21 chick embryos according
to published protocols (Shen et al., 1997). Appropriately stained embryos
were prepared and, following passage through an increasing PBTX /
glycerol concentration series, stored in 100% glycerol for photography.
For in situ hybridisation of serial sections, three different clones of the
cMid1 coding sequence were used to generate 35S-labelled anti-sense
RNA probes: a full-length 2.0 kb clone (9B1); the 1.4kb clone (7B2)
representing the 3' half of the open reading frame linearised with NsiI,
and; a 350bp fragment from the 3' end encompassing nucleotides 1906
to 2255. This 350bp PCR fragment was synthesised using clone 7B2 as
template with the following primers: 5’-CCG GAA TTC TCC CAA TAG
AGC CT-3’ and 5’-CCG GAA TTC TTT TCA GTT CTG GC-3’ (EcoRI
restriction sites incorporated into the primer sequences are in bold). The
resultant fragment was isolated and cloned into the EcoRI site of pBluescript
KS+. All three probes gave similar results. Chicken Sox10 was gener-
ously provided by P. Scotting (Cheng et al., 2000). MF-20 monoclonal
antibody supernatant (Developmental Studies Hybridoma Bank, Iowa)
was used undiluted. All embryos were fixed in 4% paraformaldehyde in
phosphate buffered saline at 4°C overnight and then embedded in wax.
Sections were dewaxed and alternate slides used either for in situ
hybridisation or for immunocytochemistry. In situ hybridisation was done
as described (Rowe et al., 1991). MF-20 staining was detected using an
alkaline phosphatase conjugated anti-mouse secondary antibody (The
Jackson Laboratory, Bar Harbor, Maine) and immersion in 5-bromo-4-
chloro-3-indolyl phosphate, p toluidine salt (BCIP), nitro blue
tetrazoliumchloride (NBT) substrate.
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